DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
A phase 1/2 trial of DOC1021 in melanoma, run by Diakonos Oncology Corporation, now recruiting.
Overview
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma is a phase 1/2 interventional study registered as NCT07288112 by Diakonos Oncology Corporation, with 35 participants planned, started 2026-04-06 and due to reach its primary completion in 2031-01. Interventions recorded: DOC1021, Tumor resection and pIFN (peginterferon alfa-2a).
Setting
Clinical Study of DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Phase
Phase 1/2
Sponsor
Diakonos Oncology Corporation
Registry
Enrolled
35
Similar pages
not linked directly; found by shared links- TrialDOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Shares DOC1021, Diakonos Oncology and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares Melanoma and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialNeoadjuvant L19IL2/L19TNF- Pivotal Study
Shares Melanoma and the tag pipeline.
- TrialEfficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Shares Melanoma and the tag pipeline.
- TrialAMT-253 in Patients With Advanced Solid Tumours
Shares Melanoma and the tag pipeline.
- TrialSCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Shares Melanoma and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Shares Melanoma and the tag pipeline.